Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation-Reference-Cited by-同舟云学术

Inhalable ceftazidime-roflumilast powder targeting infection and inflammation: Influence of incorporating roflumilast into ceftazidime-leucine co-amorphous formulation

Published:2022-11 Issue: Volume:180 Page:260-268
ISSN:0939-6411
Container-title:European Journal of Pharmaceutics and Biopharmaceutics
language:en
Short-container-title:European Journal of Pharmaceutics and Biopharmaceutics

Author:

Raj Adhikari Bishal,Sinha Shubhra,Lyons Nikita,Pletzer Daniel,Lamont Iain,Gordon Keith C.,Das Shyamal C.

Funder

University of Otago

Publisher

Elsevier BV

Subject

Pharmaceutical Science,General Medicine,Biotechnology

Reference55 articles.

1. Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis;Schäfer;BMC Pulm. Med.,2018

2. Inflammation: A two-edged sword-the model of bronchiectasis;Cole;Eur J Respir Dis Suppl,1986

3. Bronchiectasis;O'Donnell;Chest,2008

4. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis;Martinez-Garcia;Chest,2007

5. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial;Konstan;J. Cyst. Fibros.,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and characterization of co-amorphous griseofulvin/L-leucin by modified solvent processing hot-melt extrusion;International Journal of Pharmaceutics;2024-03

2. Amorphization of Low Soluble Drug with Amino Acids to Improve Its Therapeutic Efficacy: a State-of-Art-Review;AAPS PharmSciTech;2023-12-07